Motion analysis device specialist dorsaVi (ASX: DVL) has entered a commercial research project with heralded American physician Dr Chiarg Patel that will explore innovative assessment techniques for ankles and feet during sporting events and training.
More specifically, the study aims to uncover patterns and traits that could increase the risk of injury in elite athletes.
It will leverage dorsaVi’s cutting-edge wearable sensor technology and advanced artificial intelligence (AI) and machine learning algorithms to generate key insights into the movement of sportspeople.
The project will be conducted in the first half of the 2025 calendar year. It is expected to generate close to US$50,000 in revenue for the company with potential for a broadened collaboration between the duo if the initial study proves to be fruitful.
Leading sports physician
Dr Patel is regarded as a global authority in lower extremity sports medicine, specialising in injury prevention, performance optimisation, and athlete longevity. Amongst others, he acts as a ‘Resident Injury Expert’ for revered American sports broadcaster, ESPN.
Dr Patel is the also managing director of New Horizons Foot and Ankle Associates and New Horizons Concierge Sports Medicine and Peak Performance Laser Institute. In addition, he is the founder and chief executive officer of Health AnalySYST.
New Horizons specialises in non-invasive sports medicine and performance solutions for elite athletes. Its clients include sportspeople from globally recognised American sports leagues such as the National Basketball Association (NBA), National Football Association (NFL), and Major League Baseball (MLB).
Meanwhile, Health AnalySYST generates actionable insights to optimise outcomes and reduce injury risks in athletes by leveraging data-driven metrics that help enhance longevity, safety, and performance.
Benefits of dorsaVi’s technology
According to the company, Dr Patel opted to implement dorsaVi sensors for the project due to various advantages over competitors.
Notably, the group’s movement analysis sensors are commercially available in America having attained clearance from the US Food and Drug Administration (FDA). The company also possesses deep AI and algorithmic capabilities and is recognised for its expertise in lower limb products within the US sporting and clinical markets.
Blockchain integration to boost security
Management believes dorsaVi’s planned integration of blockchain technology to enhance security and compliance for its products could benefit the data attained in Dr Patel’s study.
In essence, blockchain technology helps to provide a secure and tamper-proof platform for storing data and sharing it with stakeholders. Such traits reinforce trust and reliability in the generated intelligence.
In November, dorsaVi commenced a study to gauge the merits of implementing blockchain technology into its core data platform, as it looks to enhance data integrity, storage security, and privacy controls for enterprise-grade applications.
Subsequently, the company entered a collaborative partnership with Secret Network – a leader in privacy-preserving blockchain technologies – to test the technical feasibility of integrating its proprietary devices with Secret Network’s encrypted technology.
This collaboration aims to secure user movement data collected for injury prevention, rehabilitation, and performance enhancement.